BIAF

8-K - bioAffinity Technologies, Inc. (0001712762) (Filer)

Standard-of-care imaging and risk models indicated cancer after lung screening revealed 30-millimeter pulmonary nodule CyPath® Lung test affirmed physician's assessment that the nodule could be inflammation, not cancer; nodule resolved upon follow-up scan Noninvasive CyPath® Lung performed with 92% sensitivity, 87% specificity and 88% accuracy for detecting lung cancer in more difficult to diagnose small nodules in a clinical trial of patients at high risk for lung cancer bioAffinity Technologies, Inc. (NASDAQ:BIAF, BIAFW)), a biotechnology company advancing noninvasive diagnostics for lung cancer and other lung diseases, today released a new clinical case study illustrating how CyPat

8-K - bioAffinity Technologies, Inc. (0001712762) (Filer)

Invitation-only conference focuses on the evolving landscape of lung cancer risk and early detection when the disease is most treatable bioAffinity Technologies Chief Medical Officer Gordon Downie, MD, PhD, to participate in panel on lung nodule management bioAffinity Technologies, Inc. (NASDAQ:BIAF, BIAFW)), a biotechnology company focused on noninvasive diagnostics and early cancer detection, announces that its CyPath® Lung test will be featured at the invitation-only "Advances in Early Lung Cancer Detection" symposium at the Cleveland Clinic in Cleveland, Ohio, on April 16, 2026. Gordon Downie, MD, PhD, bioAffinity Technologies' Chief Medical Officer, will be one of three panelists d

8-K - bioAffinity Technologies, Inc. (0001712762) (Filer)

Noninvasive diagnostic continues to gain traction in the current and expanding U.S. addressable market of $3.58 billion for pulmonary nodule management and surveillance of lung cancer survivors Flow cytometry+AI technology has potential to improve lung cancer risk assessment and nodule management bioAffinity Technologies, Inc. (NASDAQ:BIAF, BIAFW)), a biotechnology company focused on noninvasive diagnostics and early cancer detection, today announced that unit sales for its CyPath® Lung diagnostic in the first quarter of 2026 exceeded internal projections and, based on preliminary unaudited data, achieved 146% growth compared to the first quarter of 2025, reflecting accelerating physici

8-K - bioAffinity Technologies, Inc. (0001712762) (Filer)

8-K - bioAffinity Technologies, Inc. (0001712762) (Filer)

Panel of leading pulmonologists will share real-world patient cases and benefits of clinical use of the noninvasive CyPath® Lung diagnostic test First of "CyPath® Lung in Practice" webinar series focuses on need for greater certainty when diagnosing indeterminate pulmonary nodules Healthcare providers can register here for the April 8, 2026, webinar bioAffinity Technologies, Inc. (NASDAQ:BIAF, BIAFW)), a biotechnology company focused on noninvasive diagnostics and early cancer detection, today announced it will host the first of a series of live virtual physician roundtables featuring pulmonologists who will discuss their use of CyPath® Lung in clinical practice as part of a comprehen

8-K - bioAffinity Technologies, Inc. (0001712762) (Filer)

CyPath® Lung improves diagnostic clarity in patients with multiple lung nodules In this case study, CyPath® Lung "Unlikely Malignancy" result supported physician's decision to wait before ordering an invasive lung biopsy In a clinical study, noninvasive CyPath® Lung test demonstrated 92% sensitivity, 87% specificity and 88% accuracy for detecting lung cancer in small nodules less than 20 millimeters bioAffinity Technologies, Inc. (NASDAQ:BIAF, BIAFW)), a biotechnology company advancing noninvasive diagnostics for lung cancer and other lung diseases, today released a new clinical case study that highlights the benefit of adding CyPath® Lung, a noninvasive test for lung cancer, to the d

DEF 14A - bioAffinity Technologies, Inc. (0001712762) (Filer)

10-K - bioAffinity Technologies, Inc. (0001712762) (Filer)

8-K - bioAffinity Technologies, Inc. (0001712762) (Filer)

Laboratory business streamlined in 2025 to focus on profitable diagnostic testing services including the Company's high-value CyPath® Lung test Number of CyPath® Lung tests performed in 2025 increased by 99% compared to 2024 Orders for CyPath® Lung by physicians and clinics rose 67% YoY due to peer-to-peer marketing, positive real-world experiences and growing test awareness bioAffinity Technologies, Inc. (NASDAQ:BIAF, BIAFW)), a biotechnology company focused on the need for noninvasive, accurate tests for the detection of early-stage lung cancer and other lung diseases, today reported financial results for the year ended December 31, 2025. 2025 Highlights Record CyPath® Lung Rev

8-K - bioAffinity Technologies, Inc. (0001712762) (Filer)

Study to evaluate clinical performance of CyPath® Lung for the early detection of lung cancer in high-risk patients Murtha Cancer Center Research Program at Uniformed Services University of the Health Sciences provides support for longitudinal study bioAffinity Technologies, Inc. (NASDAQ:BIAF, BIAFW)), a biotechnology company focused on non-invasive diagnostics and early cancer detection, today announced initiation of the Company's planned large-scale, longitudinal clinical study for CyPath® Lung, its noninvasive diagnostic test for the detection of early-stage lung cancer. The 2,000-patient longitudinal study is designed to evaluate the clinical performance of the CyPath® Lung flow c

8-K - bioAffinity Technologies, Inc. (0001712762) (Filer)

PRE 14A - bioAffinity Technologies, Inc. (0001712762) (Filer)

8-K - bioAffinity Technologies, Inc. (0001712762) (Filer)

Poster presented to medical and drug industry conferees at prestigious American Academy of Allergy, Asthma & Immunology (AAAAI) Annual Meeting Research demonstrates the technology's ability to identify drug antibody receptors in sputum for two leading asthma therapies bioAffinity Technologies, Inc. (NASDAQ:BIAF, BIAFW)), a biotechnology company focused on noninvasive diagnostics and early cancer detection, today announced the presentation of a new scientific poster reporting on the ability of the Company's innovative diagnostic approach to identify antibody drug receptors in sputum, including receptors for dupilumab, a leading therapy for asthma and chronic obstructive pulmonary disease

8-K - bioAffinity Technologies, Inc. (0001712762) (Filer)

Validating sample collection by deep suction has potential to accelerate and expand adoption of CyPath® Lung bioAffinity Technologies, Inc. (NASDAQ:BIAF, BIAFW)), a biotechnology company focused on noninvasive diagnostics and early cancer detection, today announced a new study with Brooke Army Medical Center (BAMC) to validate the clinical utility of using the CyPath® Lung diagnostic test to assess sputum samples obtained by tracheal and bronchial suctioning for early detection of lung cancer. The study is designed to enroll approximately 30-50 patients undergoing routine tracheal or bronchial suctioning, with results from the study expected by mid-year 2026. Validating the performance

8-K - bioAffinity Technologies, Inc. (0001712762) (Filer)

CyPath® Lung test supported recommendation for surveillance strategy, rather than subjecting elderly patient to an invasive, risky and costly biopsy procedure Despite a suspicious nodule during a low-dose CT scan, a repeat scan showed no nodules in the lungs, validating the decision made with CyPath® Lung's results Noninvasive CyPath® Lung test has shown 92% sensitivity, 87% specificity and 88% accuracy for detecting lung cancer in small nodules less than 2 centimeters bioAffinity Technologies, Inc. (NASDAQ:BIAF, BIAFW)), a biotechnology company advancing noninvasive diagnostics for lung cancer and other lung diseases, today released a new clinical case study in which its CyPath® Lung